{
    "nct_id": "NCT05387265",
    "official_title": "A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101)",
    "inclusion_criteria": "* Histologically confirmed metastatic or locally advanced unresectable solid tumor. Must have received prior standard therapy.\n* Measurable disease per RECIST 1.1\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Adequate baseline laboratory values\n* Patients of childbearing potential or those with partners of childbearing potential must agree to use a highly effective method of birth control from signing the ICF, and for a period of 30 days after the last dose of CX-904.\n* Additional inclusion criteria may apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of malignancy that was active within the previous 2 years. Exceptions include localized cancers that are not related to the current cancer being treated, that are considered to have been cured, and in the opinion of the Investigator, present a low risk of recurrence\n* Screening electrocardiogram demonstrating a mean QTcF value > 480 msec; a screening echocardiogram with left ventricular ejection fraction (LVEF) < 50%\n* Serious concurrent illness including\n\n  * History of or current active autoimmune diseases\n  * History of myocarditis regardless of the cause\n* Pregnant or breast feeding\n* Additional exclusion criteria may apply",
    "miscellaneous_criteria": ""
}